Grange, Dorothy K |
| Recruiting | 2 | 20 | Europe, US | ER004 | EspeRare Foundation, Pierre Fabre Medicament, Iqvia Pty Ltd | X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) | 04/25 | 01/29 | | |
NCT05795361: Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome |
|
|
| Available | N/A | | Europe, US, RoW | Idursulfase-IT, HGT-2310, TAK-609 | Takeda | Hunter Syndrome | | | | |
Siminerio, Linda |
NCT04678661: My Dose Coach Mobile App to Support Insulin Titration and Maintenance |
|
|
| Terminated | N/A | 60 | US | Smartphone application and web portal, My Dose Coach, Standard Insulin Therapy Education | Linda Siminerio, Sanofi | Diabetes Mellitus Type 2 - Insulin-Treated | 12/22 | 02/23 | | |
TREAT-ED, NCT06626347: Telemedicine for Reach, Education, Access, and Treatment for Diabetes Self-Management Education and Support |
|
|
| Enrolling by invitation | N/A | 48 | US | TREAT-ED Virtual Group Diabetes Self-Management Education and Support | University of Pittsburgh, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type 1 Diabetes (T1D) | 12/25 | 05/26 | | |
Libman, Ingrid |
| Active, not recruiting | 2 | 140 | Europe, US, RoW | Ladarixin, allosteric inhibitor of CXCL8 (IL-8), CXCR1 and CXCR2 receptors, Placebo | Dompé Farmaceutici S.p.A, Dompe farmaceutici s.p.a. | Recent Onset type1 Diabetes | 04/24 | 04/26 | | |
NCT05743244: Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D) |
|
|
| Recruiting | 2 | 78 | US | Abrocitinib 200 MG Oral Tablet, CIBINQO, Ritlecitinib, Placebo | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Pfizer | Diabetes Mellitus, Type 1 | 06/26 | 06/27 | | |
NCT03929601: Rituximab-pvvr and Abatacept Vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes |
|
|
| Recruiting | 2 | 74 | US, RoW | Rituximab-pvvr, Ruxience, Abatacept, Orencia, Sterile Sodium Chloride, 0.9% Sodium Chloride Water for Injection | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH) | Type 1 Diabetes Mellitus | 10/27 | 10/29 | | |
| Active, not recruiting | 2 | 101 | US, RoW | Antithymocyte Globulin, Thymoglobulin, Placebo (for ATG) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes Mellitus, Type 1 | 12/28 | 12/29 | | |
| Recruiting | N/A | 80 | US | DVx-T1D™ app | Carnegie Mellon University, University of Pittsburgh | Diabetes Mellitus, Type 1, Behavior, Health | 12/24 | 06/25 | | |
TREAT-ED, NCT06626347: Telemedicine for Reach, Education, Access, and Treatment for Diabetes Self-Management Education and Support |
|
|
| Enrolling by invitation | N/A | 48 | US | TREAT-ED Virtual Group Diabetes Self-Management Education and Support | University of Pittsburgh, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type 1 Diabetes (T1D) | 12/25 | 05/26 | | |
Triulzi, Darrell |
| Recruiting | 3 | 160 | Europe, US, RoW | Red Blood Cell, Red blood cell (RBC), Standard of care | University of Pittsburgh, National Heart, Lung, and Blood Institute (NHLBI) | Sickle Cell Disease | 05/26 | 05/26 | | |
NCT03633604: Expanded Access IND Administration of HBOC-201 in Patients With Severe Acute Anemia |
|
|
| Available | N/A | | US | HBOC-201, Hemopure, hemoglobin glutamer - 250 (bovine) | Jonathan H. Waters, HbO2 Therapeutics LLC | Anemia Severe | | | | |
McCormick, Meghan |
No trials found |